Patient Enrollment Expands for Phase II Heart Trial


December 15, 2008

December 15, 2008 - Two additional hospitals in the U.S. opened patient enrollment for CardioVascular BioTherapuetics Inc.’s ACORD Phase II clinical trial for the treatment of severe coronary heart disease.

The sites are Minneapolis Heart Institute Foundation in Minneapolis MN, and Princeton Baptist Medical Center in Birmingham, AL.

Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati, OH were first to open for enrollment in early September, and are working in collaboration to screen and treat patients in the trial.

The ACORD (Angiogenesis for the treatment of CORonary heart Disease) trial for the treatment of severe coronary heart disease will include four randomized, double-blind, placebo-controlled doses in approximately 120 patients with severe coronary heart disease. Thirty sites are expected to participate.

For more information: